Back to Journals » Journal of Blood Medicine » Volume 1
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
L-CBM signaling in lymphocyte development and function
Authors Hara H, IIzasa E, Nakaya, Yoshida
Published 4 June 2010 Volume 2010:1 Pages 93—104
DOI https://doi.org/10.2147/JBM.S9772
Review by Single anonymous peer review
Peer reviewer comments 2
Hiromitsu Hara, Eiichi IIzasa, Mako Nakaya, Hiroki Yoshida
Department of Biomolecular Sciences, Faculty of Medicine, Saga University, Saga, Japan
Abstract: The nuclear factor-κB (NF-κB) plays a central role in the activation and survival of lymphocytes. NF-κB, therefore, is pivotal for acquired immunity, but the dysregulation of NF-κB signaling leads to inflammatory diseases and lymphomagenesis. Accumulating evidence has demonstrated that the mucosa-associated lymphoid tissue (MALT) lymphomarelated molecules, B-cell lymphoma 10 (BCL10) and MALT-lymphoma-translocation gene1 (MALT1), are essential signaling components for NF-κB and mitogen-activated protein kinase (MAPK) activation, mediated by the immunoreceptor tyrosine-based activation motif (ITAM)-coupled receptors involved in both innate and adaptive immunity. CARMA1 (also referred to as CARD11 and Bimp3) is a crucial regulator for ITAM-mediated signaling as it forms a complex with BCL10-MALT1 in lymphoid lineage cells such as T, B, natural killer (NK), and natural killer T (NKT) cells, known as the lymphoid CARMA1-BCL10-MALT1 (L-CBM) complex. In this review, recent understanding of the molecular and biological functions and the signal regulation mechanisms of the L-CBM complex are described and its role in disease development and potential as a therapeutic target is further discussed.
Keywords: lymphocytes, inflammatory disease, immunity L-CBM complex
© 2010 The Author(s). This work is published and licensed by Dove Medical Press Limited. The
full terms of this license are available at https://www.dovepress.com/terms.php
and incorporate the Creative Commons Attribution
- Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted
without any further permission from Dove Medical Press Limited, provided the work is properly
attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.